A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders

Abstract Objective. To evaluate the benefit of pharmacogenetics in antidepressant treatment. Methods. In a simulated trial 100,000 subjects in a current episode of major depressive disorder (MDD) received citalopram or bupropion based on the clinician's decision (algorithm A) or following indic...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:The world journal of biological psychiatry Ročník 12; číslo 7; s. 501 - 515
Hlavní autoři: Serretti, Alessandro, Olgiati, Paolo, Bajo, Emanuele, Bigelli, Marco, De Ronchi, Diana
Médium: Journal Article
Jazyk:angličtina
Vydáno: England Informa Healthcare 01.10.2011
Taylor & Francis
Témata:
antidepressants
Antidepressive Agents - economics
Antidepressive Agents - therapeutic use
Bupropion - economics
Bupropion - therapeutic use
Citalopram - economics
Citalopram - therapeutic use
Computer Simulation
cost-benefit
Cost-Benefit Analysis - methods
Depression
Depressive Disorder, Major - drug therapy
Depressive Disorder, Major - economics
Depressive Disorder, Major - genetics
Genetic Testing - economics
Humans
Meta-Analysis as Topic
Models, Psychological
pharmacoeconomics
pharmacogenetics
Pharmacogenetics - economics
Pharmacogenetics - methods
Serotonin Plasma Membrane Transport Proteins
ISSN:1562-2975, 1814-1412, 1814-1412
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract Abstract Objective. To evaluate the benefit of pharmacogenetics in antidepressant treatment. Methods. In a simulated trial 100,000 subjects in a current episode of major depressive disorder (MDD) received citalopram or bupropion based on the clinician's decision (algorithm A) or following indications from 5-HTTLPR genetic testing (algorithm B), which effect size of was estimated from a meta-analysis of pharmacogenetic trials. A and B were compared in a cost-utility analysis (12 weeks). Costs (international $, 2010) were drawn from official sources. Treatment effects were expressed as quality-adjusted life weeks (QALWs). Outcome was incremental cost-effectiveness ratio (ICER). Results. Under base-case conditions, genetic test use was associated with increases in antidepressant response (0.062 QALWs) and tolerability (0.016 QALWs) but cost benefit was not acceptable (ICER = $2,890; $1,800-$4,091). However, when the joint effect on antidepressant response and tolerability was analyzed in two recurrent episodes, ICER dropped to $1,392 ($837-$1,982). Cost-effectiveness acceptability curve (CEAC) showed a >80% probability that ICER value fell below the commonly accepted 3 times Gross Domestic Product (GDP) threshold (World Health Organization) and therefore suggesting cost-effectiveness. Conclusion. Notwithstanding some caveats (exclusion of gene-gene and gene-environment interactions; simple 5-HTTLPR architecture), this simulation is favourable to incorporate pharmacogenetic test in antidepressant treatment.
AbstractList To evaluate the benefit of pharmacogenetics in antidepressant treatment.OBJECTIVETo evaluate the benefit of pharmacogenetics in antidepressant treatment.In a simulated trial 100,000 subjects in a current episode of major depressive disorder (MDD) received citalopram or bupropion based on the clinician's decision (algorithm A) or following indications from 5-HTTLPR genetic testing (algorithm B), which effect size of was estimated from a meta-analysis of pharmacogenetic trials. A and B were compared in a cost-utility analysis (12 weeks). Costs (international $, 2010) were drawn from official sources. Treatment effects were expressed as quality-adjusted life weeks (QALWs). Outcome was incremental cost-effectiveness ratio (ICER).METHODSIn a simulated trial 100,000 subjects in a current episode of major depressive disorder (MDD) received citalopram or bupropion based on the clinician's decision (algorithm A) or following indications from 5-HTTLPR genetic testing (algorithm B), which effect size of was estimated from a meta-analysis of pharmacogenetic trials. A and B were compared in a cost-utility analysis (12 weeks). Costs (international $, 2010) were drawn from official sources. Treatment effects were expressed as quality-adjusted life weeks (QALWs). Outcome was incremental cost-effectiveness ratio (ICER).Under base-case conditions, genetic test use was associated with increases in antidepressant response (0.062 QALWs) and tolerability (0.016 QALWs) but cost benefit was not acceptable (ICER = $2,890; $1,800-$4,091). However, when the joint effect on antidepressant response and tolerability was analyzed in two recurrent episodes, ICER dropped to $1,392 ($837-$1,982). Cost-effectiveness acceptability curve (CEAC) showed a >80% probability that ICER value fell below the commonly accepted 3 times Gross Domestic Product (GDP) threshold (World Health Organization) and therefore suggesting cost-effectiveness.RESULTSUnder base-case conditions, genetic test use was associated with increases in antidepressant response (0.062 QALWs) and tolerability (0.016 QALWs) but cost benefit was not acceptable (ICER = $2,890; $1,800-$4,091). However, when the joint effect on antidepressant response and tolerability was analyzed in two recurrent episodes, ICER dropped to $1,392 ($837-$1,982). Cost-effectiveness acceptability curve (CEAC) showed a >80% probability that ICER value fell below the commonly accepted 3 times Gross Domestic Product (GDP) threshold (World Health Organization) and therefore suggesting cost-effectiveness.Notwithstanding some caveats (exclusion of gene-gene and gene-environment interactions; simple 5-HTTLPR architecture), this simulation is favourable to incorporate pharmacogenetic test in antidepressant treatment.CONCLUSIONNotwithstanding some caveats (exclusion of gene-gene and gene-environment interactions; simple 5-HTTLPR architecture), this simulation is favourable to incorporate pharmacogenetic test in antidepressant treatment.
Abstract Objective. To evaluate the benefit of pharmacogenetics in antidepressant treatment. Methods. In a simulated trial 100,000 subjects in a current episode of major depressive disorder (MDD) received citalopram or bupropion based on the clinician's decision (algorithm A) or following indications from 5-HTTLPR genetic testing (algorithm B), which effect size of was estimated from a meta-analysis of pharmacogenetic trials. A and B were compared in a cost-utility analysis (12 weeks). Costs (international $, 2010) were drawn from official sources. Treatment effects were expressed as quality-adjusted life weeks (QALWs). Outcome was incremental cost-effectiveness ratio (ICER). Results. Under base-case conditions, genetic test use was associated with increases in antidepressant response (0.062 QALWs) and tolerability (0.016 QALWs) but cost benefit was not acceptable (ICER = $2,890; $1,800-$4,091). However, when the joint effect on antidepressant response and tolerability was analyzed in two recurrent episodes, ICER dropped to $1,392 ($837-$1,982). Cost-effectiveness acceptability curve (CEAC) showed a >80% probability that ICER value fell below the commonly accepted 3 times Gross Domestic Product (GDP) threshold (World Health Organization) and therefore suggesting cost-effectiveness. Conclusion. Notwithstanding some caveats (exclusion of gene-gene and gene-environment interactions; simple 5-HTTLPR architecture), this simulation is favourable to incorporate pharmacogenetic test in antidepressant treatment.
To evaluate the benefit of pharmacogenetics in antidepressant treatment. In a simulated trial 100,000 subjects in a current episode of major depressive disorder (MDD) received citalopram or bupropion based on the clinician's decision (algorithm A) or following indications from 5-HTTLPR genetic testing (algorithm B), which effect size of was estimated from a meta-analysis of pharmacogenetic trials. A and B were compared in a cost-utility analysis (12 weeks). Costs (international $, 2010) were drawn from official sources. Treatment effects were expressed as quality-adjusted life weeks (QALWs). Outcome was incremental cost-effectiveness ratio (ICER). Under base-case conditions, genetic test use was associated with increases in antidepressant response (0.062 QALWs) and tolerability (0.016 QALWs) but cost benefit was not acceptable (ICER = $2,890; $1,800-$4,091). However, when the joint effect on antidepressant response and tolerability was analyzed in two recurrent episodes, ICER dropped to $1,392 ($837-$1,982). Cost-effectiveness acceptability curve (CEAC) showed a >80% probability that ICER value fell below the commonly accepted 3 times Gross Domestic Product (GDP) threshold (World Health Organization) and therefore suggesting cost-effectiveness. Notwithstanding some caveats (exclusion of gene-gene and gene-environment interactions; simple 5-HTTLPR architecture), this simulation is favourable to incorporate pharmacogenetic test in antidepressant treatment.
Objective. To evaluate the benefit of pharmacogenetics in antidepressant treatment. Methods. In a simulated trial 100,000 subjects in a current episode of major depressive disorder (MDD) received citalopram or bupropion based on the clinician's decision (algorithm A) or following indications from 5-HTTLPR genetic testing (algorithm B), which effect size of was estimated from a meta-analysis of pharmacogenetic trials. A and B were compared in a cost-utility analysis (12 weeks). Costs (international $, 2010) were drawn from official sources. Treatment effects were expressed as quality-adjusted life weeks (QALWs). Outcome was incremental cost-effectiveness ratio (ICER). Results. Under base-case conditions, genetic test use was associated with increases in antidepressant response (0.062 QALWs) and tolerability (0.016 QALWs) but cost benefit was not acceptable (ICER = $2,890; $1,800-$4,091). However, when the joint effect on antidepressant response and tolerability was analyzed in two recurrent episodes, ICER dropped to $1,392 ($837-$1,982). Cost-effectiveness acceptability curve (CEAC) showed a >80% probability that ICER value fell below the commonly accepted 3 times Gross Domestic Product (GDP) threshold (World Health Organization) and therefore suggesting cost-effectiveness. Conclusion. Notwithstanding some caveats (exclusion of gene-gene and gene-environment interactions; simple 5-HTTLPR architecture), this simulation is favourable to incorporate pharmacogenetic test in antidepressant treatment.
Author De Ronchi, Diana
Serretti, Alessandro
Olgiati, Paolo
Bajo, Emanuele
Bigelli, Marco
Author_xml – sequence: 1
  givenname: Alessandro
  surname: Serretti
  fullname: Serretti, Alessandro
  email: alessandro.serretti@unibo.it, alessandro.serretti@unibo.it
  organization: Institute of Psychiatry, University of Bologna
– sequence: 2
  givenname: Paolo
  surname: Olgiati
  fullname: Olgiati, Paolo
  email: alessandro.serretti@unibo.it, alessandro.serretti@unibo.it
  organization: Institute of Psychiatry, University of Bologna
– sequence: 3
  givenname: Emanuele
  surname: Bajo
  fullname: Bajo, Emanuele
  email: alessandro.serretti@unibo.it, alessandro.serretti@unibo.it
  organization: Department of Management, University of Bologna
– sequence: 4
  givenname: Marco
  surname: Bigelli
  fullname: Bigelli, Marco
  email: alessandro.serretti@unibo.it, alessandro.serretti@unibo.it
  organization: Department of Management, University of Bologna
– sequence: 5
  givenname: Diana
  surname: De Ronchi
  fullname: De Ronchi, Diana
  email: alessandro.serretti@unibo.it, alessandro.serretti@unibo.it
  organization: Institute of Psychiatry, University of Bologna
BackLink https://www.ncbi.nlm.nih.gov/pubmed/21595526$$D View this record in MEDLINE/PubMed
BookMark eNqFkU2P0zAQhi20iP2Af4CQb8AhxU7iOOawaLUCFqkSCJWzNXEmrSvHLrYL2n-Pq24PcFhOnsPzvBrPe0nOfPBIyEvOFg1n6h0XXV0rKRY143whZK1U_4Rc8J63FW95fVbmglQH5pxcprRlrJFK8WfkvOZCCVF3F8Td0DmM6GgO1HoT4i5EyEjX6DFbQzOmbP2avhHV3Wq1_Pb9bcHobgNxBhNcWFsDRY4IeUafaZjoDNsQ6Yi7iCnZX0hHm0IcMabn5OkELuGLh_eK_Pj0cXV7Vy2_fv5ye7OsTMtlriSwgTMJDQ6yh6nHvptUGYQEGNpGIB-N7AYUDHjTDoNERAmm72FsTa2G5oq8PubuYvi5Lz_Qs00GnQOPYZ-0Yqxrmez7Qr56IPfDjKPeRTtDvNenAxXg_REwMaQUcdLGZsg2-BzBOs2ZPrShT23oQxv62EaR23_kU_5_tA9HzfoplDv_DtGNOsO9C3GK4I1NB_vRhOu_EjYILm8MRNTbsI--HP_xFf4A0SS1Rg
CitedBy_id crossref_primary_10_1016_j_neulet_2018_06_020
crossref_primary_10_1016_j_cll_2016_05_001
crossref_primary_10_1007_s11055_017_0411_5
crossref_primary_10_1007_s41669_017_0014_7
crossref_primary_10_1016_j_microc_2024_111159
crossref_primary_10_1080_20523211_2024_2410197
crossref_primary_10_1016_j_jad_2017_11_004
crossref_primary_10_1038_s41397_021_00249_1
crossref_primary_10_1007_s40273_013_0107_9
crossref_primary_10_3109_15622975_2012_665477
crossref_primary_10_1007_s11920_015_0594_9
crossref_primary_10_1016_j_euroneuro_2013_08_008
crossref_primary_10_1371_journal_pone_0146262
crossref_primary_10_1016_j_metabol_2012_08_021
crossref_primary_10_1016_j_pnpbp_2011_08_013
crossref_primary_10_1080_17425255_2019_1658742
crossref_primary_10_1111_trf_12805
crossref_primary_10_2217_pgs_11_125
crossref_primary_10_1007_s40273_022_01185_z
crossref_primary_10_1002_hup_2232
crossref_primary_10_2217_pgs_11_95
crossref_primary_10_1002_ajmg_b_32184
crossref_primary_10_1007_s00228_020_02866_4
crossref_primary_10_1002_hup_2433
crossref_primary_10_1016_j_euroneuro_2011_10_003
crossref_primary_10_1038_tpj_2017_21
crossref_primary_10_1517_17425255_2014_928693
crossref_primary_10_2217_npy_12_73
Cites_doi 10.2165/00023210-200822110-00005
10.1016/j.biopsych.2010.04.034
10.1111/j.2044-8260.1967.tb00530.x
10.1016/j.jpsychires.2007.05.012
10.1111/j.1600-0447.2007.01136.x
10.1176/ajp.2006.163.9.1569
10.1002/ajmg.b.20015
10.1192/bjp.bp.108.062521
10.1111/j.1524-4733.2008.00388.x
10.1097/01.jcp.0000095350.32154.73
10.1038/npp.2009.50
10.1007/s00213-009-1550-3
10.1034/j.1399-0004.2000.580508.x
10.1176/appi.ajp.163.11.1905
10.1001/jama.287.14.1840
10.1016/j.jad.2008.07.004
10.1002/ajmg.b.30027
10.1016/S0165-0327(98)00138-4
10.1016/j.psychres.2007.12.012
10.1186/1479-7364-3-3-257
10.4088/JCP.v66n0803
10.1001/jama.296.13.1609
10.1097/01213011-200502000-00001
10.1177/0269881109106953
10.1038/sj.mp.4000816
10.1176/ps.2009.60.11.1446
10.1176/ps.2006.57.5.673
10.1016/j.biopsych.2008.03.030
10.1016/S0006-3223(01)01283-5
10.4088/JCP.v64n0406
10.4088/JCP.v68n1211
10.3109/15622975.2010.486842
10.1002/ajmg.b.30816
10.1016/j.biopsych.2008.06.009
10.1016/S0929-6646(08)60060-1
10.1046/j.1525-1497.1998.00201.x
10.1086/503820
10.1345/aph.1A099
10.1016/j.jad.2009.01.027
10.1016/j.eurpsy.2009.07.012
10.1038/sj.tpj.6500477
10.1007/s11920-008-0013-6
10.1111/j.1600-0447.2005.00684.x
10.1192/bjp.187.2.106
10.1007/s00127-009-0091-8
10.1001/jama.1996.03540150055031
10.1186/1477-7525-2-20
10.1016/j.clinthera.2007.04.018
10.1001/archpsyc.61.11.1163
10.3109/15622970701432528
10.1186/1471-244X-9-38
10.1093/schbul/sbn114
10.1007/s00228-003-0692-1
10.1111/j.1742-1241.2007.01335.x
10.1176/appi.ajp.2007.06071225
10.1080/15622970903131886
10.1016/j.psychres.2009.01.005
10.1097/YPG.0b013e3283050aca
10.2165/00023210-200418130-00006
10.1080/15622970701691503
10.2165/00002018-200831100-00004
10.1186/1744-859X-8-14
10.1038/sj.mp.4000425
10.1016/S0165-0327(97)00117-1
10.1176/appi.ps.56.9.1153
10.1097/00004850-200505000-00005
10.1038/sj.mp.4001926
10.1023/A:1021265303283
10.1016/S0893-133X(00)00132-9
10.1016/S0165-0327(02)00049-6
10.1034/j.1600-0447.108.s418.15.x
10.1176/ajp.157.1.1
10.1038/mp.2008.116
10.1176/appi.ajp.162.7.1243
10.3949/ccjm.75.1.57
10.1016/j.eurpsy.2007.11.001
10.1057/jors.1988.132
10.1371/journal.pmed.0050045
10.4088/JCP.v66n0210
10.1001/archpsyc.64.7.783
10.1038/mp.2008.32
10.2217/14622416.7.2.159
10.1097/01.nmd.0000154837.49247.96
10.1097/YPG.0b013e32832a506e
10.1086/503850
10.2165/00019053-200927060-00006
10.1126/science.1083968
ContentType Journal Article
Copyright 2011 Informa Healthcare 2011
Copyright_xml – notice: 2011 Informa Healthcare 2011
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.3109/15622975.2011.572998
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1814-1412
EndPage 515
ExternalDocumentID 21595526
10_3109_15622975_2011_572998
572998
Genre Research Article
Clinical Trial
Journal Article
GroupedDBID ---
00X
03L
0BK
0R~
123
29R
2WC
4.4
53G
5VS
AAFWK
AAGKR
AAJNR
AALIY
AALUX
AAMIU
AAPUL
AAQRR
ABBKH
ABDBF
ABEIZ
ABEJY
ABIVO
ABLKL
ABPTK
ABUPF
ACENM
ACFUF
ACGFS
ACLSK
ADCVX
ADFCX
ADRBQ
AECIN
AENEX
AEOZL
AEYQI
AFKVX
AFWLO
AGDLA
AGFJD
AGRBW
AGYJP
AIJEM
AIRBT
AJWEG
AKBVH
ALIIL
ALMA_UNASSIGNED_HOLDINGS
ALQZU
AMDAE
AWYRJ
BABNJ
BEYMU
BLEHA
BOHLJ
BSQBA
CAG
CCCUG
COF
CS3
CXMEQ
DKSSO
DU5
EBD
EBS
EJD
EMOBN
ESX
F5P
H13
HZ~
KRBQP
KSSTO
KWAYT
KYCEM
LJTGL
M44
M4Z
O9-
P2P
RNANH
RVRKI
SV3
TFDNU
TFL
TFW
TUS
TWFNG
UEQFS
V1S
~1N
AAGDL
ABJNI
ABLIJ
ABWVI
ABXYU
ACIEZ
ACSXF
ACUHS
AFRVT
ALYBC
AQTUD
TASJS
TBQAZ
TDBHL
TERGH
TUROJ
AAYXX
ACUYY
ADSTP
CITATION
ADYSH
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c417t-7a0b107a3eb78af8e86f98af57aab435e1dc76be50a134bb7eee7ac88ad4c29b3
IEDL.DBID TFW
ISICitedReferencesCount 32
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000296238500004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1562-2975
1814-1412
IngestDate Thu Sep 04 16:50:06 EDT 2025
Mon Jul 21 05:58:05 EDT 2025
Sat Nov 29 05:58:05 EST 2025
Tue Nov 18 21:48:22 EST 2025
Mon Oct 20 23:41:06 EDT 2025
Wed Jun 21 01:44:28 EDT 2023
IsPeerReviewed true
IsScholarly true
Issue 7
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c417t-7a0b107a3eb78af8e86f98af57aab435e1dc76be50a134bb7eee7ac88ad4c29b3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
PMID 21595526
PQID 900640788
PQPubID 23479
PageCount 15
ParticipantIDs informahealthcare_journals_10_3109_15622975_2011_572998
crossref_citationtrail_10_3109_15622975_2011_572998
crossref_primary_10_3109_15622975_2011_572998
informaworld_taylorfrancis_310_3109_15622975_2011_572998
proquest_miscellaneous_900640788
pubmed_primary_21595526
PublicationCentury 2000
PublicationDate 20111000
10/1/2011
2011-10-00
2011-Oct
20111001
PublicationDateYYYYMMDD 2011-10-01
PublicationDate_xml – month: 10
  year: 2011
  text: 20111000
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle The world journal of biological psychiatry
PublicationTitleAlternate World J Biol Psychiatry
PublicationYear 2011
Publisher Informa Healthcare
Taylor & Francis
Publisher_xml – name: Informa Healthcare
– name: Taylor & Francis
References CIT0071
CIT0076
Golenko-Ginzburg D (CIT0028) 1988; 39
CIT0075
CIT0077
Serretti A (CIT0084) 2007; 8
Munafo MR (CIT0057) 2009; 65
CIT0079
Banks S (CIT0008) 1998; 26
CIT0086
CIT0089
Cascade E (CIT0015) 2009; 6
CIT0088
Keers R (CIT0042) 2011; 138
Andronis L (CIT0002) 2009
Min W (CIT0054) 2009; 205
CIT0004
CIT0009
Kirsch I (CIT0046) 2008; 5
CIT0094
CIT0093
CIT0098
Adler DA (CIT0001) 2006; 163
CIT0092
Serretti A (CIT0082) 2005; 15
CIT0091
Melartin TK (CIT0053) 2005; 66
Nieuwstraten C (CIT0060) 2001; 35
Judd LL (CIT0037) 1998; 50
Grassi L (CIT0029) 2009; 8
Gartlehner G (CIT0026) 2008; 31
Hewett K (CIT0031) 2010; 24
Walsh BT (CIT0099) 2002; 287
CIT0014
Fenwick E (CIT0024) 2005; 187
Tournier M (CIT0096) 2009; 115
Sarnes MW (CIT0078) 2004; 13
Warden D (CIT0100) 2007; 164
CIT0021
Aydemir O (CIT0006) 2009; 20
Cheng IC (CIT0017) 2007; 106
Posternak MA (CIT0070) 2003; 75
Bender A (CIT0011) 2008; 10
Lepine JP (CIT0050) 2001; 62
CIT0027
Moller HJ (CIT0055) 2003
Weinstein MC (CIT0102) 1996; 276
CIT0034
National Collaborating Centre for Mental Health (CIT0059) 2005
CIT0033
Kato M (CIT0040) 2005; 20
Hu XZ (CIT0032) 2006; 78
Serretti A (CIT0083) 2007; 12
Khan A (CIT0044) 2006; 39
Watkins KE (CIT0101) 2009; 12
Pezawas L (CIT0066) 2008; 13
Birnbaum HG (CIT0012) 2009; 27
Bellivier F (CIT0010) 2004; 124
Hughes S (CIT0035) 2009; 118
Hamilton M (CIT0030) 1967; 6
CIT0036
Arranz M (CIT0005) 2008; 34
Soeteman DI (CIT0090) 2005; 56
Papakostas GI (CIT0064) 2010; 11
Serna M (CIT0080) 2010; 25
APA (CIT0003) 2000; 157
Cuffel BJ (CIT0019) 2003; 64
Thase ME (CIT0095) 2005; 66
Lazary J (CIT0049) 2008; 64
Koponen H (CIT0047) 2010; 11
Smeraldi E (CIT0087) 1998; 3
Demyttenaere K (CIT0020) 2001; 62
Eker SS (CIT0023) 2009; 10
Kendler KS (CIT0043) 2005; 162
Kato M (CIT0041) 2009; 167
Bradvik L (CIT0013) 2008; 117
Comings DE (CIT0018) 2000; 58
CIT0052
Caspi A (CIT0016) 2003; 301
Papakostas GI (CIT0062) 2007; 68
Kasper S (CIT0038) 2007; 29
CIT0056
Ehli EA (CIT0022) 2011
Azimi NA (CIT0007) 1998; 13
Shaw J (CIT0085) 2002; 37
Papakostas GI (CIT0063) 2008; 42
Zetin M (CIT0103) 2006; 39
CIT0058
Perlis RH (CIT0065) 2009; 34
Kim H (CIT0045) 2006; 296
Ferrier IN (CIT0025) 1999; 60
Kato M (CIT0039) 2010; 15
CIT0067
Turecki G (CIT0097) 2001; 6
Serretti A (CIT0081) 2004; 129
Llorca PM (CIT0051) 2007; 61
Laje G (CIT0048) 2009; 60
Popp J (CIT0069) 2006; 7
Revicki D (CIT0073) 1998; 48
Rocca P (CIT0074) 2010; 45
CIT0068
Reimherr F (CIT0072) 2010; 175
References_xml – ident: CIT0086
  doi: 10.2165/00023210-200822110-00005
– ident: CIT0094
  doi: 10.1016/j.biopsych.2010.04.034
– volume: 6
  start-page: 278
  year: 1967
  ident: CIT0030
  publication-title: Br J Soc Clin Psychol
  doi: 10.1111/j.2044-8260.1967.tb00530.x
– volume: 42
  start-page: 134
  year: 2008
  ident: CIT0063
  publication-title: J Psychiatr Res
  doi: 10.1016/j.jpsychires.2007.05.012
– volume: 117
  start-page: 185
  year: 2008
  ident: CIT0013
  publication-title: Acta Psychiatr Scand
  doi: 10.1111/j.1600-0447.2007.01136.x
– volume: 163
  start-page: 1569
  year: 2006
  ident: CIT0001
  publication-title: Am J Psychiatry
  doi: 10.1176/ajp.2006.163.9.1569
– volume: 124
  start-page: 87
  year: 2004
  ident: CIT0010
  publication-title: Am J Med Genet B Neuropsychiatr Genet
  doi: 10.1002/ajmg.b.20015
– ident: CIT0034
  doi: 10.1192/bjp.bp.108.062521
– volume: 12
  start-page: 65
  year: 2009
  ident: CIT0101
  publication-title: Value Health
  doi: 10.1111/j.1524-4733.2008.00388.x
– ident: CIT0004
  doi: 10.1097/01.jcp.0000095350.32154.73
– volume: 34
  start-page: 2227
  year: 2009
  ident: CIT0065
  publication-title: Neuropsychopharmacology
  doi: 10.1038/npp.2009.50
– volume: 62
  start-page: 4
  issue: 13
  year: 2001
  ident: CIT0050
  publication-title: J Clin Psychiatry
– volume: 205
  start-page: 409
  year: 2009
  ident: CIT0054
  publication-title: Psychopharmacology
  doi: 10.1007/s00213-009-1550-3
– volume: 58
  start-page: 375
  year: 2000
  ident: CIT0018
  publication-title: Clin Genet
  doi: 10.1034/j.1399-0004.2000.580508.x
– ident: CIT0075
  doi: 10.1176/appi.ajp.163.11.1905
– volume: 287
  start-page: 1840
  year: 2002
  ident: CIT0099
  publication-title: J Am Med Assoc
  doi: 10.1001/jama.287.14.1840
– volume: 115
  start-page: 160
  year: 2009
  ident: CIT0096
  publication-title: J Affect Disord
  doi: 10.1016/j.jad.2008.07.004
– volume: 129
  start-page: 36
  year: 2004
  ident: CIT0081
  publication-title: Am J Med Genet B Neuropsychiatr Genet
  doi: 10.1002/ajmg.b.30027
– volume: 50
  start-page: 97
  year: 1998
  ident: CIT0037
  publication-title: J Affect Disord
  doi: 10.1016/S0165-0327(98)00138-4
– volume: 167
  start-page: 97
  year: 2009
  ident: CIT0041
  publication-title: Psychiatry Res
  doi: 10.1016/j.psychres.2007.12.012
– ident: CIT0021
  doi: 10.1186/1479-7364-3-3-257
– volume: 66
  start-page: 974
  year: 2005
  ident: CIT0095
  publication-title: J Clin Psychiatry
  doi: 10.4088/JCP.v66n0803
– volume: 296
  start-page: 1609
  year: 2006
  ident: CIT0045
  publication-title: J Am Med Assoc
  doi: 10.1001/jama.296.13.1609
– volume: 37
  start-page: 32
  year: 2002
  ident: CIT0085
  publication-title: Pract Pharmacoeconom
– volume: 15
  start-page: 61
  year: 2005
  ident: CIT0082
  publication-title: Pharmacogenet Genom
  doi: 10.1097/01213011-200502000-00001
– volume: 24
  start-page: 1209
  year: 2010
  ident: CIT0031
  publication-title: J Psychopharmacol
  doi: 10.1177/0269881109106953
– volume: 6
  start-page: 98
  year: 2001
  ident: CIT0097
  publication-title: Mol Psychiatry
  doi: 10.1038/sj.mp.4000816
– ident: CIT0091
– volume: 60
  start-page: 1446
  year: 2009
  ident: CIT0048
  publication-title: Psychiatr Serv
  doi: 10.1176/ps.2009.60.11.1446
– ident: CIT0092
  doi: 10.1176/ps.2006.57.5.673
– volume: 64
  start-page: 498
  year: 2008
  ident: CIT0049
  publication-title: Biol Psychiatry
  doi: 10.1016/j.biopsych.2008.03.030
– ident: CIT0071
  doi: 10.1016/S0006-3223(01)01283-5
– volume: 64
  start-page: 397
  year: 2003
  ident: CIT0019
  publication-title: J Clin Psychiatry
  doi: 10.4088/JCP.v64n0406
– volume: 68
  start-page: 1907
  year: 2007
  ident: CIT0062
  publication-title: J Clin Psychiatry
  doi: 10.4088/JCP.v68n1211
– volume: 11
  start-page: 834
  issue: 6
  year: 2010
  ident: CIT0047
  publication-title: World J Biol Psychiatry
  doi: 10.3109/15622975.2010.486842
– ident: CIT0056
  doi: 10.1002/ajmg.b.30816
– volume: 65
  start-page: 211
  year: 2009
  ident: CIT0057
  publication-title: Biol Psychiatry
  doi: 10.1016/j.biopsych.2008.06.009
– volume: 106
  start-page: 903
  year: 2007
  ident: CIT0017
  publication-title: J Formos Med Assoc
  doi: 10.1016/S0929-6646(08)60060-1
– volume: 20
  start-page: 205
  year: 2009
  ident: CIT0006
  publication-title: Turk Psikiyatri Derg
– volume: 13
  start-page: 664
  year: 1998
  ident: CIT0007
  publication-title: J Gen Intern Med
  doi: 10.1046/j.1525-1497.1998.00201.x
– volume: 138
  start-page: 145
  year: 2011
  ident: CIT0042
  publication-title: Pharmacogenom J 11
– ident: CIT0052
  doi: 10.1086/503820
– volume: 35
  start-page: 1608
  year: 2001
  ident: CIT0060
  publication-title: Ann Pharmacother
  doi: 10.1345/aph.1A099
– volume: 62
  start-page: 30
  issue: 22
  year: 2001
  ident: CIT0020
  publication-title: J Clin Psychiatry
– volume: 118
  start-page: 9
  year: 2009
  ident: CIT0035
  publication-title: J Affect Disord
  doi: 10.1016/j.jad.2009.01.027
– volume: 25
  start-page: 206
  year: 2010
  ident: CIT0080
  publication-title: Eur Psychiatry
  doi: 10.1016/j.eurpsy.2009.07.012
– volume: 8
  start-page: 90
  year: 2007
  ident: CIT0084
  publication-title: Pharmacogenom J
  doi: 10.1038/sj.tpj.6500477
– volume: 10
  start-page: 73
  year: 2008
  ident: CIT0011
  publication-title: Curr Psychiatry Rep
  doi: 10.1007/s11920-008-0013-6
– ident: CIT0014
  doi: 10.1111/j.1600-0447.2005.00684.x
– volume: 187
  start-page: 106
  year: 2005
  ident: CIT0024
  publication-title: Br J Psychiatry
  doi: 10.1192/bjp.187.2.106
– volume: 45
  start-page: 603
  year: 2010
  ident: CIT0074
  publication-title: Soc Psychiatry Psychiatr Epidemiol
  doi: 10.1007/s00127-009-0091-8
– volume: 276
  start-page: 1253
  year: 1996
  ident: CIT0102
  publication-title: J Am Med Assoc
  doi: 10.1001/jama.1996.03540150055031
– year: 2011
  ident: CIT0022
  publication-title: Mol Psychiatry
– volume: 13
  start-page: 34
  year: 2004
  ident: CIT0078
  publication-title: Manag Care
– ident: CIT0077
  doi: 10.1186/1477-7525-2-20
– ident: CIT0088
  doi: 10.1016/j.clinthera.2007.04.018
– ident: CIT0058
  doi: 10.1001/archpsyc.61.11.1163
– volume: 11
  start-page: 300
  issue: 2
  year: 2010
  ident: CIT0064
  publication-title: World J Biol Psychiatry
  doi: 10.3109/15622970701432528
– volume: 60
  start-page: 10
  issue: 6
  year: 1999
  ident: CIT0025
  publication-title: J Clin Psychiatry
– ident: CIT0079
  doi: 10.1186/1471-244X-9-38
– volume: 34
  start-page: 1130
  year: 2008
  ident: CIT0005
  publication-title: Schizophr Bull
  doi: 10.1093/schbul/sbn114
– volume-title: National Clinical Practice Guideline
  year: 2005
  ident: CIT0059
– ident: CIT0068
  doi: 10.1007/s00228-003-0692-1
– volume: 61
  start-page: 702
  year: 2007
  ident: CIT0051
  publication-title: Int J Clin Pract
  doi: 10.1111/j.1742-1241.2007.01335.x
– volume: 164
  start-page: 1189
  year: 2007
  ident: CIT0100
  publication-title: Am J Psychiatry
  doi: 10.1176/appi.ajp.2007.06071225
– volume: 39
  start-page: 6
  year: 2006
  ident: CIT0044
  publication-title: Psychopharmacol Bull
– volume: 10
  start-page: 400
  issue: 4
  year: 2009
  ident: CIT0023
  publication-title: World J Biol Psychiatry
  doi: 10.1080/15622970903131886
– volume: 175
  start-page: 67
  year: 2010
  ident: CIT0072
  publication-title: Psychiatry Res
  doi: 10.1016/j.psychres.2009.01.005
– ident: CIT0089
  doi: 10.1097/YPG.0b013e3283050aca
– ident: CIT0093
  doi: 10.2165/00023210-200418130-00006
– volume: 29
  start-page: 1
  year: 2007
  ident: CIT0038
  publication-title: World J Biol Psychiatry
  doi: 10.1080/15622970701691503
– start-page: ix
  year: 2009
  ident: CIT0002
  publication-title: Health Technol Assess 13
– volume: 31
  start-page: 851
  year: 2008
  ident: CIT0026
  publication-title: Drug Saf
  doi: 10.2165/00002018-200831100-00004
– volume: 8
  start-page: 14
  year: 2009
  ident: CIT0029
  publication-title: Ann Gen Psychiatry
  doi: 10.1186/1744-859X-8-14
– ident: CIT0036
– volume: 3
  start-page: 508
  issue: 6
  year: 1998
  ident: CIT0087
  publication-title: Mol Psychiatry
  doi: 10.1038/sj.mp.4000425
– volume: 48
  start-page: 25
  year: 1998
  ident: CIT0073
  publication-title: J Affect Disord
  doi: 10.1016/S0165-0327(97)00117-1
– volume: 56
  start-page: 1153
  year: 2005
  ident: CIT0090
  publication-title: Psychiatr Serv
  doi: 10.1176/appi.ps.56.9.1153
– volume: 6
  start-page: 16
  year: 2009
  ident: CIT0015
  publication-title: Psychiatry
– volume: 20
  start-page: 151
  year: 2005
  ident: CIT0040
  publication-title: Int Clin Psychopharmacol
  doi: 10.1097/00004850-200505000-00005
– volume: 12
  start-page: 247
  year: 2007
  ident: CIT0083
  publication-title: Mol Psychiatry
  doi: 10.1038/sj.mp.4001926
– volume: 26
  start-page: 33
  year: 1998
  ident: CIT0008
  publication-title: Admin Policy Ment Health
  doi: 10.1023/A:1021265303283
– ident: CIT0067
  doi: 10.1016/S0893-133X(00)00132-9
– volume: 75
  start-page: 115
  year: 2003
  ident: CIT0070
  publication-title: J Affect Disord
  doi: 10.1016/S0165-0327(02)00049-6
– start-page: 73
  year: 2003
  ident: CIT0055
  publication-title: Acta Psychiatr Scand
  doi: 10.1034/j.1600-0447.108.s418.15.x
– volume: 157
  start-page: 1
  year: 2000
  ident: CIT0003
  publication-title: Am J Psychiatry
  doi: 10.1176/ajp.157.1.1
– volume: 15
  start-page: 473
  year: 2010
  ident: CIT0039
  publication-title: Mol Psychiatry
  doi: 10.1038/mp.2008.116
– volume: 162
  start-page: 1243
  year: 2005
  ident: CIT0043
  publication-title: Am J Psychiatry
  doi: 10.1176/appi.ajp.162.7.1243
– ident: CIT0027
  doi: 10.3949/ccjm.75.1.57
– volume: 39
  start-page: 38
  year: 2006
  ident: CIT0103
  publication-title: Psychopharmacol Bull
– ident: CIT0009
  doi: 10.1016/j.eurpsy.2007.11.001
– volume: 39
  start-page: 767
  year: 1988
  ident: CIT0028
  publication-title: J Op Res Soc
  doi: 10.1057/jors.1988.132
– volume: 5
  start-page: e45
  year: 2008
  ident: CIT0046
  publication-title: PLoS Med
  doi: 10.1371/journal.pmed.0050045
– volume: 66
  start-page: 220
  year: 2005
  ident: CIT0053
  publication-title: J Clin Psychiatry
  doi: 10.4088/JCP.v66n0210
– ident: CIT0033
  doi: 10.1001/archpsyc.64.7.783
– volume: 13
  start-page: 709
  year: 2008
  ident: CIT0066
  publication-title: Mol Psychiatry
  doi: 10.1038/mp.2008.32
– volume: 7
  start-page: 159
  year: 2006
  ident: CIT0069
  publication-title: Pharmacogenomics
  doi: 10.2217/14622416.7.2.159
– ident: CIT0076
  doi: 10.1097/01.nmd.0000154837.49247.96
– ident: CIT0098
  doi: 10.1097/YPG.0b013e32832a506e
– volume: 78
  start-page: 815
  year: 2006
  ident: CIT0032
  publication-title: Am J Hum Genet
  doi: 10.1086/503850
– volume: 27
  start-page: 507
  year: 2009
  ident: CIT0012
  publication-title: Pharmacoeconomics
  doi: 10.2165/00019053-200927060-00006
– volume: 301
  start-page: 386
  year: 2003
  ident: CIT0016
  publication-title: Science
  doi: 10.1126/science.1083968
SSID ssj0037991
Score 2.1128612
Snippet Abstract Objective. To evaluate the benefit of pharmacogenetics in antidepressant treatment. Methods. In a simulated trial 100,000 subjects in a current...
Objective. To evaluate the benefit of pharmacogenetics in antidepressant treatment. Methods. In a simulated trial 100,000 subjects in a current episode of...
To evaluate the benefit of pharmacogenetics in antidepressant treatment. In a simulated trial 100,000 subjects in a current episode of major depressive...
To evaluate the benefit of pharmacogenetics in antidepressant treatment.OBJECTIVETo evaluate the benefit of pharmacogenetics in antidepressant treatment.In a...
SourceID proquest
pubmed
crossref
informaworld
informahealthcare
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 501
SubjectTerms antidepressants
Antidepressive Agents - economics
Antidepressive Agents - therapeutic use
Bupropion - economics
Bupropion - therapeutic use
Citalopram - economics
Citalopram - therapeutic use
Computer Simulation
cost-benefit
Cost-Benefit Analysis - methods
Depression
Depressive Disorder, Major - drug therapy
Depressive Disorder, Major - economics
Depressive Disorder, Major - genetics
Genetic Testing - economics
Humans
Meta-Analysis as Topic
Models, Psychological
pharmacoeconomics
pharmacogenetics
Pharmacogenetics - economics
Pharmacogenetics - methods
Serotonin Plasma Membrane Transport Proteins
Title A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders
URI https://www.tandfonline.com/doi/abs/10.3109/15622975.2011.572998
https://www.ncbi.nlm.nih.gov/pubmed/21595526
https://www.proquest.com/docview/900640788
Volume 12
WOSCitedRecordID wos000296238500004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAWR
  databaseName: Taylor & Francis Journals Complete
  customDbUrl:
  eissn: 1814-1412
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0037991
  issn: 1562-2975
  databaseCode: TFW
  dateStart: 20000101
  isFulltext: true
  titleUrlDefault: https://www.tandfonline.com
  providerName: Taylor & Francis
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT9wwELYKqhCXlvJooS3ygQMcLNZJHMdHVHXFgSJUbdu9WWNnwkM0QbuB348nTra0FUWitxw8iTyesWfime9jbE8RapYEL6TDVGSYV8KoSgnMwPgKAGRHBvP9RJ-eFtOpOXvQxU9llZRDVxEooturybnBdQwkhGN5GFKOhBpCIwCnCuGhoW7fcPKTZ07GP4atONXGRMDUPBEkEXvnHn3Jb2fTWo9cerGow_oDzfTxmLQ7m8av_39Wa-xVH5fyo2hIb9gLrNfZypf-5n2DXR_xjjSHtw0nQIeIf4w82B-1QfKW0Drqc76vxPFkcnL29SAM4ze_gLHJGPiirJ03Ff8JV82MD6W4d8jLHgl0vsm-jT9PPh2LnqlB-EzqVmgYuZBHQopOF1AVWOSVCQ9KA7gQkKEsvc4dqhHINHNOI6IGXxRQZj4xLt1iy3VT4zvGHWSJ9NqFOITIAqXLnQ9Bh5KYl6kpR9ssHdbI-h7GnNg0rm1IZ0iRdlCkJUXaqMhtJhZSNxHG44nx-q_lt713z5-QLB4aiW27Hy9VZEkhsX-J8sGgbHByurmBGpvbuTX9hWsY8jYa2mIWIWQzSiX5zvO_-56tJkNlo_zAltvZLX5kL_1dezmf7bIlPS12O7-6B3ROHFw
linkProvider Taylor & Francis
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELWgIOBCWz4LBXzgAAer6ySO42OFWG3V7aqqAvRm2c6kgEpSbdL-fjyxs7SgUglxy8FjxeMZ-409fkPIW4GsWdw4xi2kLIO8ZkrUgkFmlKuNMXwoBvN5LheL4vhYHcZswi6mVWIMXQeiiGGtRufGw-idIcScqB0fcyT4IjQwcAqPD1Vxm9zxSEBg9YZy-mVcjFOpVKBMzROGIuH13LW9XNmdNiJ36ddVJtZvfKbXo9Jhd5qu_4dxbZCHEZrS3WBLm-QWNI_IvYN4-f6YnO7SoW4O7VuKnA6BAhmoN0F8CUl7JOxoTug7wWZlOT88eu-b0bNf3NhoD3SV2U7bmv4w39slHbNxL4BWkQy0e0I-TT-WH2YsFmtgLuOyZ9JMrA8lTQpWFqYuoMhr5T-ENMZ6TAa8cjK3ICaGp5m1EgCkcUVhqswlyqZPyVrTNvCcUGuyhDtpPRTBeoHc5tZ53CE45FWqqskWScdJ0i4ymWNBjVPtIxpUpB4VqVGROihyi7CV1Flg8rihvfxj_nV08O4GyeKyleh-OHupQ6EUFPubKB0tSns_x8sb00B73mkV71x9k2fB0laj8KhNCZHkL_75j9-Q-7PyYK7ne4v9l-RBMuY58m2y1i_P4RW56y76b93y9eBdPwFTSB8w
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagoKqXtrz6oIAPHOBgdZ3EcXysaFdFLKsVWqA3y3bGtFWbrHbT_v564mQpoFIJbjl4ong8Y38Tz3xDyFuBrFncOMYtpCyD3DMlvGCQGeW8MYa3zWC-jeR4XJycqMmtKn5Mq8QY2keiiHavRueelX6_jTAHaj-EHAkWhEYCThHgoSoekkd5QOdo19Ph934vTqVSkTE1TxiKxOK5O9_yy-G02VGXni4TsX6jM70blLaH03Dj_6e1SdY7YEoPoiU9IQ-gekpWP3dX78_IxQFtu-bQpqbI6BAJkIEGA8Q6SNogXUf1g74T7Hg6HU2-vA_D6OwnMzZaA13mtdPa00tzXs9pn4t7DbTsqEAXz8nX4dH0wzHrWjUwl3HZMGkGNgSSJgUrC-MLKHKvwoOQxtiAyICXTuYWxMDwNLNWAoA0rihMmblE2fQFWanqCrYJtSZLuJM2ABHsFshtbl1AHYJDXqaqHOyQtF8j7Toec2yncaFDPIOK1L0iNSpSR0XuELaUmkUej3vGyz-WX3fuvbhHsrhtJLpp_7z42CYFxf4mSnuD0sHL8erGVFBfLbTqblzDkK1oaMtZBMymhEjy3X_-4jdkdXI41KOP408vyVrSJznyPbLSzK_gFXnsrpuzxfx161s3BU8d8Q
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+model+to+incorporate+genetic+testing+%285-HTTLPR%29+in+pharmacological+treatment+of+major+depressive+disorders&rft.jtitle=The+world+journal+of+biological+psychiatry&rft.au=Serretti%2C+Alessandro&rft.au=Olgiati%2C+Paolo&rft.au=Bajo%2C+Emanuele&rft.au=Bigelli%2C+Marco&rft.date=2011-10-01&rft.issn=1562-2975&rft.eissn=1814-1412&rft.volume=12&rft.issue=7&rft.spage=501&rft.epage=515&rft_id=info:doi/10.3109%2F15622975.2011.572998&rft.externalDBID=n%2Fa&rft.externalDocID=10_3109_15622975_2011_572998
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1562-2975&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1562-2975&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1562-2975&client=summon